In recent years, FGF19 has emerged as an attractive target for treating chronic liver diseases where bile acids play pivotal roles, and to this end, an engineered nontumorigenic analog of FGF19, NGM282 (also known as M70) (15), is currently being evaluated as a potential treatment for patients with nonalcoholic steatohepatitis, primary sclerosing cholangitis, or primary biliary cholangitis (16, 17). Here, FGF19 is linked to primary biliary cholangitis.